Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
3 authors.
Yan LiDepartment of Neurology, School of Medicine, Washington University, St. Louis, Missouri, USA.
Lon S SchneiderDepartment of Psychiatry and The Behavioral Sciences, Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
DIAN-TU Primary Prevention Trial NfL Characterization Admin SuppU01AG059798 · NIA · WASHINGTON UNIVERSITY · PI MCDADE, ERIC MARTIN · 2018 to 2025
$97.9M
DIAN-TU: Tau Next Generation Prevention Trial - Administrative SupplementR01AG068319 · NIA · WASHINGTON UNIVERSITY · PI RANDALL J BATEMAN · 2020 to 2026
$81.4M
Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical TrialR01AG063826 · NIA · UNIVERSITY OF ARIZONA · PI BRINTON, ROBERTA EILEEN, RODGERS, KATHLEEN E. · 2019 to 2025
$37.2M
DIAN-TU Next Generation Prevention Trial - Data Request Management SupplementR01AG053267 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2017 to 2023
$34.9M
USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HELENA Chang CHUI, ARTHUR W TOGA · 2020 to 2026
$27.8M
Dominantly Inherited Alzheimer's Network Trials Unit - Adaptive Prevention TrialR01AG046179 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2014 to 2019
$26.6M
Alzheimer's Prevention Initiative ADAD Colombia TrialR01AG055444 · NIA · BANNER HEALTH · PI LOPERA, FRANCISCO, REIMAN, ERIC MICHAEL · 2017 to 2022
$14.9M
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.R01AG074983 · NIA · INSTITUTE FOR MOLECULAR MEDICINE · PI Michael G Agadjanyan, LON S SCHNEIDER · 2022 to 2026
$12.4M
Novel Cognitive and Functional Measures for Alzheimer's Disease Prevention Trials: Sensitivity to BiomarkersR01AG051346 · NIA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI GOLDBERG, TERRY, HARVEY, PHILIP D. · 2018 to 2022
$9.8M
DOMINANTLY INHERITED ALZHEIMER NETWORK TRIAL: AN OPPORTUNITY TO PREVENT DEMENTIAU01AG042791 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2013 to 2018
$8.9M
(-)-Phenserine inhibition of neuronal death in Alzheimer’s disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trialR01AG062687 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BALLARD, CLIVE, SCHNEIDER, LON S · 2019 to 2023
$3.8M
Delivery of Essential Fatty Acids to the Brain in Alzheimer's 1U01 AG059798Delivery of Essential Fatty Acids to the Brain in Alzheimer's P01 AG02350Delivery of Essential Fatty Acids to the Brain in Alzheimer's R01 AG053267-S1Delivery of Essential Fatty Acids to the Brain in Alzheimer's U01 AG042791-S1 (FNIH and Accelerating Medicines Partnership)NIA NIH HHS P30 AG066530NIA NIH HHS R01 AG046179NIA NIH HHS R01 AG051346NIA NIH HHS R01 AG053267NIA NIH HHS R01 AG055444NIA NIH HHS R01 AG062687NIA NIH HHS R01 AG063826NIA NIH HHS R01 AG068319NIA NIH HHS R01 AG074983NIA NIH HHS U01 AG042791NIA NIH HHS U01 AG059798State of California
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Letter to the Editor. · full record | OpenQuestion